ADAP News and Press, Adaptimmune Therapeutics plc From 05/19/21

- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- Adaptimmun...

Adaptimmune Therapeutics (ADAP) posts preclinical data from the company's mesothelin HiT program demonstrating antigen-specific tumor cell killing in vitro and complete tumor regression in an animal model.The company's HLA-independent TCR targeting mesothelin induced complete regression in a ...

- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies - PHILADELPHIA and OXFORDSHIRE, Unit...

Adaptimmune Therapeutics plc (ADAP) Q1 2021 Earnings Conference Call May 06, 2021, 09:00 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer Karen Mil...

- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1 - - Astellas nominates second t...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astell...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the US market...

Achilles Therapeutics has filed proposed terms for a $176 million U.S. IPO. The firm is developing treatment candidates for various cancers. ACHL won't have data readout until the second half of 2022 for its Phase 1 safety trials, so the IPO may be more suited to institutional inv...

Instil Bio has filed terms for its $250 million IPO. The firm is advancing autologous TIL treatment candidates for melanoma and other solid tumor cancers. TIL has produced intriguing early efficacy results but the IPO is priced far above the normal life science IPO range, so I'll ...

Adaptimmune Therapeutics PLC (ADAP) Q4 2020 Earnings Conference Call February 25, 2020 08:00 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer Confe...